Antitumor effect of immunization with fusion of dendritic cells and hepatocellular carcinoma cells in mice

Hepatobiliary and Pancreatic Diseases International

Volumn 3, Issue 2, 2004, Pages 235-240

  Zhang, Hao ^a   Zheng, Shu Sen ^a   Jiang, Guo Ping ^a   Wu, Li Hua ^a   Zhu, Fen ^a   Yang, Zhen Lin ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cell fusion; Dendritic cells; Hepatocellular carcinoma

Indexed keywords

GAMMA INTERFERON; LACTATE DEHYDROGENASE; MACROGOL; MAJOR HISTOCOMPATIBILITY ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURVIVAL; CANCER TRANSPLANTATION; CARCINOMA CELL; CELL FUSION; CELL TRANSPLANTATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HYBRIDOMA CELL CULTURE; IMMUNIZATION; IMMUNOMODULATION; LIVER CELL CARCINOMA; LYMPHOCYTE ACTIVATION; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROVOCATION TEST; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR IMMUNITY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL FUSION; DENDRITIC CELLS; FEMALE; HYBRIDOMAS; IMMUNIZATION; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; NEOPLASM TRANSPLANTATION; TUMOR CELLS, CULTURED;

EID: 2442650315     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000;232:10-24.
2. Shen BY, Li HW, Regimbeau JM, Belghiti J. Recurrence after resection of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2002;1:401-405.
3. Tang ZY. Small hepatocellular carcinoma: current status and prospects. Hepatobiliary Pancreat Dis Int 2002;1:349-353.
4. Sun XY, Wu ZD, Hu JB. Suicide gene therapy of hepatocellular carcinoma and delivery procedure and route of therapeutic gene in vivo. Hepatobiliary Pancreat Dis Int 2002;1:373-377.
5. Blum HE. Molecular therapy and prevention of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2003;2:11-22.
6. Palmieri G, Montella L, Milo M, Fiore R, Biondi E, Bianco AR, et al. Ultra-low-dose interleukin-2 in unresectable hepatocellular carcinoma. Am J Clin Oncol 2002;25:224-226.
7. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
8. Yi Q. Dendritic cell-based immunotherapy in multiple myeloma. Leuk Lymphoma 2003;44:2031-2038.
9. Turtle CJ, Hart DN. Dendritic cells in tumor immunology and immunotherapy. Curr Drug Targets 2004;5:17-39.
10. Dallal RM, Lotze MT. The dendritic cell and human cancer vaccines. Curr Opin Immunol 2000;12:583-588.
11. Ueno H, Tcherepanova I, Reygrobellet O, Laughner E, Ventura C, Palucka AK, et al. Dendritic cell subsets generated from CD34(+) hematopoietic progenitors can be transfected with mRNA and induce antigen-specific cytotoxic T cell responses. J Immunol Methods 2004;285:171-180.
12. Strome SE, Voss S, Wilcox R, Wakefield TL, Tamada K, Flies D, et al. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res 2002; 15;62:1884-1889.
13. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000;6:332-336.
14. Homma S, Toda G, Gong J, Kufe D, Ohno T. Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. J Gastroenterol 2001;36:764-771.
15. Siders WM, Vergilis KL, Johnson C, Shields J, Kaplan JM. Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. Mol Ther 2003;7:498-505.
16. Soruri A, Fayyazi A, Neumann C, Schlott T, Jung T, Matthes C, et al. Ex vivo generation of human anti-melanoma autologous cytolytic T cells by dentritic cell/melanoma cell hybridomas. Cancer Immunol Immunother 2001;50:307-314.
17. Azuma T, Horie S, Tomita K, Takahashi T, Tanaka Y, Kashiwase K, et al. Dendritic cell immunotherapy for patients with metastatic renal cell carcinoma: University of Tokyo experience. Int J Urol 2002;9:340-346.
18. Ehtesham M, Kabos P, Gutierrez MA, Samoto K, Black KL, Yu JS. Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats. J Immunother 2003;26:107-116.
19. Kaminski ER, Goddard RV, Prentice AG. Dendritic cells and their potential therapeutic role in haematological malignancy. Leuk Lymphoma 2003;44:1657-1666.
20. Ridolfi R, Ridolfi L, Petrini M, Fiammenghi L, Riccobon A. Dendritic cell vaccination and immunostimulation in advanced melanoma. Expert Rev Vaccines 2003;2:825-833.
21. Bremers AJ, Parmiani G. Immunology and immunotherapy of human cancer: present concepts and clinical developments. Crit Rev Oncol Hematol 2000;34:1-25.
22. Piemonti L, Zerbi A, Di Carlo V. Strategies for tumor immune escape. Drugs Today 2003;39:701-724.
23. Kakumu S, Ito S, Ishikawa T, Mita Y, Tagaya T, Fukuzawa Y, et al. Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J Gastroenterol Hepatol 2000;15:431-436.
24. Moingeon P. Cancer vaccines. Vaccine 2001;19:1305-1326.
25. Gong J, Koido S, Chen D, Tanaka Y, Huang L, Avigan D, et al. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood 2002;99:2512-2517.
26. Kjaergaard J, Shimizu K, Shu S. Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell Immunol 2003;225:65-74.
27. Sloan AE, Parajuli P. Human autologous dendritic cell-glioma fusions: feasibility and capacity to stimulate T cells with proliferative and cytolytic activity. J Neurooncol 2003;64:177-183.
28. Celluzzi CM, Falo LD Jr. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol 1998; 160:3081-3085.
29. Li J, Holmes LM, Franek KJ, Burgin KE, Wagner TE, Wei Y. Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity. Cancer Immunol Immunother 2001;50:456-462.
30. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001;193:233-238.